Myeloma Foundation Uses Patient Connections To Help Speed Drug Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bolstered by a huge patient database, the Multiple Myeloma Research Consortium is helping to speed trials of new therapies, including some of the most talked about investigational drugs in the disease space, like carfilzomib and pomalidomide.
You may also be interested in...
Dart Therapeutics: Backed By Non-Profits, Open To Venture
Dart Therapeutics is owned and funded by rare disease patient foundations, and tiny ones at that. But with its first candidate, for Duchenne muscular dystrophy, it has created a special ownership structure to move the program forward. That takes a page from the recent private investor playbook, and Dart’s CEO wants to use venture capital to fund more programs without losing its patient-centric vision and grassroots passion.
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.